|
|
|
|
Tempus Ai Inc (NASDAQ: TEM) |
|
Price: $60.9800
$0.34 
0.561%
|
| Day's High:
| $62.98
| Week Perf:
| 5.47 %
|
| Day's Low: |
$ 59.98 |
30 Day Perf: |
-13.02 % |
| Volume (M): |
8,280 |
52 Wk High: |
$ 91.45 |
| Volume (M$): |
$ 504,911 |
52 Wk Avg: |
$53.53 |
| Open: |
$61.75 |
52 Wk Low: |
$31.36 |
|
|
| Market Capitalization (Millions $) |
10,397 |
| Shares
Outstanding (Millions) |
171 |
| Employees |
1,052 |
| Revenues (TTM) (Millions $) |
949 |
| Net Income (TTM) (Millions $) |
-775 |
| Cash Flow (TTM) (Millions $) |
-13 |
| Capital Exp. (TTM) (Millions $) |
25 |
Tempus Ai Inc
Company Address: 600 West Chicago Avenue Chicago 60654 IL
Company Phone Number: 976-5448 Stock Exchange / Ticker: NASDAQ TEM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Thu, Jul 10 2025 5:08 PM UTC
Investor Alert: Tempus AI, Inc. Faces Class Action Lawsuit Amid Investor LossesIn a significant development for shareholders of Tempus AI, Inc. (NASDAQ: TEM), the Pomerantz Law Firm has announced the initiation of a class action lawsuit against the company, marking an escalating concern over the firm?s performance and disclosure practices. This lawsuit serves as a crucial r...
|
| Business Update
Published Mon, May 5 2025 3:08 PM UTC
Leveraging AI in Psychiatry: Tempus Notetaker Revolutionizes Clinical DocumentationIn a significant leap for mental health care, Tempus AI, Inc. has unveiled its latest innovation, Notetaker, an artificial intelligence-driven clinical assistant designed to foster efficiency and enhance precision in psychiatric practice. As mental health professionals grapple with the chall...
|
| Business Update
Published Sun, Apr 20 2025 6:24 AM UTC
Tempus AI Enlists Top Physicians to Revolutionize Oncology Research with New Advisory Board Tempus AI, Inc. (NASDAQ: TEM), a Chicago-based leader in AI-driven precision medicine, has made a significant stride in advancing oncology research through the establishment of a distinguished advisory board. This move marks a pivotal moment as the company continues to forge a path to...
|
| Business Update
Published Sun, Mar 30 2025 5:48 AM UTC
Precision Medicine Revolution: Tempus AI s Groundbreaking Exhibitions at the 2025 American College of Cardiology Annual Meeting In the rapidly evolving domain of precision medicine, Tempus AI, Inc. (NASDAQ: TEM) stands as a pioneering force bridging the worlds of artificial intelligence (AI) and healthcare. In a significant stride towards revolutionizing patient care, the co...
|
| Product Service News
Published Fri, Feb 21 2025 4:32 PM UTC
In an era where artificial intelligence (AI) and precision medicine are becoming integral to cancer treatment, a significant collaboration has emerged between Tempus AI, Inc. and Stemline Therapeutics, a subsidiary of the Menarini Group. Announced on February 21, 2025, this partnership aims to leverage Tempus s Next AI-enabled care pathway intelligence platform to enhance ca...
|
| Per Share |
Current |
| Earnings (TTM) |
-656.51 $ |
| Revenues (TTM) |
5.57 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.89 $
|
| Book Value |
1.91 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-656.51 $
|
| Revenues (TTM) |
5.57 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.89 $
|
| Book Value |
1.91 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
